Human Neutralizing Antibodies Against Mers Coronavirus: Implications for Future Immunotherapy

Tang, Xian; Marasco, Wayne A.

doi:10.2217/imt.15.33

Cited by 7 publications

(6 citation statements)

References 14 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Natural variation in F506 had been reported for England-1 MERS-CoV, which was isolated from the second MERS patient from Qatar [40]. Given viral infection and neutralization escape, we termed "divergent combination immunotherapy" [41] and suggested investigating the cooperation of the more potent neutralizing mAbs with the cross-neutralized protective mAbs. Our results indicated that 13 mAbs present diverse binding phenotypes of competing ability with MERS-GD27 or MERS-GD33, which suggests divergent epitopes.…”

Section: Discussionmentioning

confidence: 99%

Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient

Niu

Zhang

Zhou

et al. 2018

The Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient

Niu

Zhang

Zhou

et al. 2018

The Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Although researchers have identified several anticoronavirus drugs that target molecules and signaling pathways such as ACE2 or interferon signaling, they possess limited clinical utility and cannot resolve all clinical problems. [ 22 , 23 ] In this study, clinical bioinformatics was used to conduct a multi-omics association analysis of immune-related molecules following SARS-CoV-2 infection, in order to identify drugs that not only resist coronavirus infection but also regulate coronavirus-related immune abnormalities. Chang et al [ 24 ] found that Polygonum cuspidatum could be used as an anti-SARS virus therapy.…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics analysis of SARS-CoV-2 infection-associated immune injury and therapeutic prediction for COVID-19

Zhang¹,

Chen²,

Zhang³

et al. 2021

Emergency and Critical Care Medicine

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus 2 is a highly contagious viral infection, without any available targeted therapies. The high mortality rate of COVID-19 is speculated to be related to immune damage. Methods: In this study, clinical bioinformatics analysis was conducted on transcriptome data of coronavirus infection. Results: Bioinformatics analysis revealed that the complex immune injury induced by coronavirus infection provoked dysfunction of numerous immune-related molecules and signaling pathways, including immune cells and toll-like receptor cascades. Production of numerous cytokines through the Th17 signaling pathway led to elevation in plasma levels of cytokines (including IL6, NF-κB, and TNF-α) followed by concurrent inflammatory storm, which mediates the autoimmune response. Several novel medications seemed to display therapeutic effects on immune damage associated with coronavirus infection. Conclusions: This study provided insights for further large-scale studies on the target therapy on reconciliation of immunological damage associated with COVID-19.

show abstract

“…42 A recent review evaluated the potential therapeutic monoclonal antibodies and animal models of MERS. 43,44 They described seven neutralizing antibodies panned with full-length spike protein on paramagnetic proteoliposomes and mammalian cells with the ability to bind to MERS-CoV RBD with potent neutralizing activity. Animal model studies and clinical trials are pending.…”

Section: Passive Immune Therapymentioning

confidence: 99%

Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma

Lindholm

Ramsey

Kwaan

2020

Semin Thromb Hemost

View full text Add to dashboard Cite

In the ongoing pandemic of coronavirus disease 2019 (COVID-19), the novel virus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is infecting a naïve population. The innate immunity of the infected patient is unable to mount an effective defense, resulting in a severe illness with substantial morbidity and mortality. As most treatment modalities including antivirals and anti-inflammatory agents are mostly ineffective, an immunological approach is needed. The mechanism of innate immunity to this viral illness is not fully understood. Passive immunity becomes an important avenue for the management of these patients. In this article, the immune responses of COVID-19 patients are reviewed. As SARS-CoV-2 has many characteristics in common with two other viruses, SARS-CoV that cause severe acute respiratory syndrome (SARS) and MERS-CoV (Middle East respiratory syndrome coronavirus) that causes Middle East respiratory syndrome (MERS), the experiences learned from the use of passive immunity in treatment can be applied to COVID-19. The immune response includes the appearance of immunoglobulin M followed by immunoglobulin G and neutralizing antibodies. Convalescent plasma obtained from patients recovered from the illness with high titers of neutralizing antibodies was successful in treating many COVID-19 patients. The factors that determine responses as compared with those seen in SARS and MERS are also reviewed. As there are no approved vaccines against all three viruses, it remains a challenge in the ongoing development for an effective vaccine for COVID-19.

show abstract

Human Neutralizing Antibodies Against Mers Coronavirus: Implications for Future Immunotherapy

Cited by 7 publications

References 14 publications

Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient

Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient

Bioinformatics analysis of SARS-CoV-2 infection-associated immune injury and therapeutic prediction for COVID-19

Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma

Contact Info

Product

Resources

About